![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW RECENT DEVELOPMENTS IN DES FOR LONG LESIONS
The Journal of Cardiovascular Surgery 2019 August;60(4):433-8
DOI: 10.23736/S0021-9509.19.10965-2
Copyright © 2019 EDIZIONI MINERVA MEDICA
language: English
Drug-eluting stents for PAD: what does (all) the data tell us?
John PHILLIPS ✉
MidOhio Cardiology and Vascular Consultants, Columbus, OH, USA
When the FDA approved the use of a paclitaxel-coated stent in the peripheral arteries in November of 2012, a new era in the treatment of peripheral arterial disease (PAD) emerged. This marked, for the first time in the United States, that a drug-eluting device was available to treat this complex arterial bed, and has likely changed forever how PAD is treated. Prior to this, US physicians had been using drug-eluting stents (DES) in the coronary arteries for 8 years with exceptional results in both safety and efficacy. Since the Zilver®PTX® (Cook Medical, Bloomington, IN USA) was released, multiple drug-coated balloons (DCB) with paclitaxel have been approved in the US, as has another DES, the Eluvia™ stent (Boston Scientific, Minneapolis, MN USA).
KEY WORDS: Drug-eluting stent; Peripheral arterial disease; Paclitaxel; Femoral artery